Ernexa (ERNA) news

Recent news

Ernexa Therapeutics - on track for IND submission Q3 2026 and Phase 1 trial Q4 2026

AInvest Wire · Jul 15, 2026

Ernexa Therapeutics CEO corner highlights differentiated Erna-101 platform as company advances toward planned first-in-human Phase 1 study in 2026

AInvest Wire · Jul 14, 2026

Eterna Therapeutics announces $9.2M convertible debt and warrant financing

AInvest Wire · Dec 15, 2023

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by